Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 5, 2025Diabetes Obesity and MetabolismOpen Access

Cardiovascular and kidney outcomes of GLP‐1 receptor agonists in adults with obesity: A target trial emulation study

View Full Paper
Ask AI
Bookmark
Share

Authors

HTHuilin TangYLYiwen LuBZBingyu Zhang

Discussion

Loading...

Member takes

Overview

Target trial emulation reveals GLP-1 receptor agonists reduce cardiovascular and kidney risks in adults with obesity, suggesting strong benefits over other anti-obesity medications.

Key Points

  • GLP-1 receptor agonists significantly lower the risk of major cardiovascular events and kidney issues in adults with obesity.
  • With 140,169 matched participants, GLP-1RAs showed a hazard ratio of 0.76 for major adverse cardiovascular events compared to other treatments.
  • Use of GLP-1 receptor agonists also resulted in improved mental health outcomes, including reduced risks of depression and suicidal ideation.
  • Risks of acute pancreatitis and gastrointestinal issues were not significantly increased with GLP-1 receptor agonist use.

Cite This Study

Tang et al. (2025) studied this question.

synapsesocial.com/papers/68c23922b210217d6477a51ahttps://doi.org/10.1111/dom.70054
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association2021 · 3,717 citations
  2. 2A global federated real-world data and analytics platform for research2023 · 823 citations
  3. 3Effects of once-weekly semaglutide 2.4 mg on C-reactive protein in adults with overweight or obesity (STEP 1, 2, and 3): exploratory analyses of three randomised, double-blind, placebo-controlled, phase 3 trials2022 · 96 citations